Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera ...

Cabozantinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor, a drug used as a therapy for several ...

The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, psoriasis, ...

Intas Pharmaceuticals has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs ...

Illumina is expanding access to its oncology range of in vitro diagnostic (IVD) tests, as the company's TruSight Oncology (TSO) Comprehensive IVD is now covered under Medicare. This coverage also ...